Literature DB >> 2804346

A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma.

A Casonato1, L De Marco, M Mazzucato, V De Angelis, D De Roia, F Fabris, Z M Ruggeri, A Girolami.   

Abstract

A case is reported of a 49-year-old woman with a mild bleeding tendency. Her bleeding time, platelet count and size, plasma ristocetin cofactor activity, von Willebrand factor (vWF) antigen, and vWF multimeric pattern are all within normal limits. Spontaneous platelet aggregation is observed when citrated platelet-rich plasma (PRP) is stirred in an aggregometer cuvette. This aggregation is completely is only slightly diminished by an antiglycoprotein (GP) IIb/IIIa or by an anti GPIb monoclonal antibody. The patient's PRP shows increased sensitivity to ristocetin. The distinct feature of this patient, also present in two family members studied, is that platelet aggregation is initiated by purified vWF in the absence of any other agonist. The vWF-induced platelet aggregation is abolished by anti-GPIb and anti-GPIIb/IIIa monoclonal antibodies and by EDTA (5 mmol/L). Apyrase inhibits the second wave of aggregation. Patient's platelets in PRP are four to six times more reactive to asialo vWF-induced platelet aggregation than normal platelets. The amount of radiolabeled vWF bound to platelets in the presence of either low concentration of ristocetin or asialo vWF was increased 30% compared with normal. The patient's platelet GPIb was analyzed by SDS page and immunoblotting and by binding studies with anti-GPIb monoclonal antibodies showed one band with slightly increased migration pattern and a normal number of GPIb molecules. Unlike the previously reported patients with pseudo or platelet-type von Willebrand disease, this patient has normal vWF parameters.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804346

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

2.  Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival.

Authors:  Alessandra Casonato; Eva Galletta; Federico Galvanin; Viviana Daidone
Journal:  EJHaem       Date:  2021-05-05

3.  Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.

Authors:  A Casonato; E Pontara; A Bertomoro; D Dannhauser; S Secchiero; M Zaninotto; A Girolami
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

4.  Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease.

Authors:  Alessandra Casonato; Maria Grazia Cattini; Viviana Daidone; Elena Pontara; Antonella Bertomoro; Paolo Prandoni
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

5.  Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue.

Authors:  Alessandra Casonato; Viviana Daidone; Eva Galletta; Antonella Bertomoro
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

6.  Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia.

Authors:  Qi Wang; Lijuan Cao; Guangying Sheng; Hongjie Shen; Jing Ling; Jundan Xie; Zhenni Ma; Jie Yin; Zhaoyue Wang; Ziqiang Yu; Suning Chen; Yiming Zhao; Changgeng Ruan; Lijun Xia; Miao Jiang
Journal:  Clin Appl Thromb Hemost       Date:  2018-08-13       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.